AdaptImmune partners to advance promising cancer immunotherapies

Adaptimmune has entered into a collaboration and license agreement with Alpine Immune Sciences to advance Adaptimmune's next-generation SPEAR T-Cell products under development to treat a variety of cancers. Under the terms of the deal, Seattle-based Alpine Immune Sciences (NASDAQ: ALPN) will receive a $2 million upfront payment from Adaptimmune (NASDAQ: ADAP), which is based in Philadelphia and Oxfordshire, England. Alpine could earn up to an additional $288 million in development and commercializati on…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news